Synaffix’s most recent open-access manuscript covering a 360° insight into their GlycoConnect technology for best-in-class ADCs is now published in MAbs! Since the original 2015 paper, many improvements were made in all critical elements of the technology, including enzyme engineering, antibody remodelling, manufacturing of UDP-azidosugar and linker-drugs, metal-free click conjugation and most importantly, the tremendous positive impact of GlycoConnect™ technology on preclinical-therapeutic-index. Read the full article here.
